2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.098 Charles Logan NACLC23 Abstract

PP01.098 Charles Logan NACLC23 Abstract

Pdf Summary

This study investigated the association between upstaging and overall survival among patients with tumors ranging from 2cm to 3cm who received different surgical treatments for lung cancer. The researchers used the National Cancer Database to identify patients who underwent either anatomic sublobar resection (segmentectomy) or lobectomy for stage I non-small-cell lung cancer between 2010 and 2017. Patients who underwent other types of surgeries or had missing stage information were excluded.<br /><br />The study included a total of 25,844 patients, with 1,291 receiving segmentectomy and 24,553 receiving lobectomy. Results showed that 13.3% of those who received segmentectomy and 18.1% of those who received lobectomy were upstaged to pathological stage II or greater (a higher stage). The propensity-score matched cohort, which included 2,580 patients, was balanced, with 50% receiving segmentectomy. Among this cohort, 6.7% of patients were upstaged after segmentectomy and 9.1% after lobectomy. <br /><br />The study found that upstaging after segmentectomy was associated with similar overall survival compared to upstaging after lobectomy. This was observed in both unadjusted and adjusted Cox models as well as Kaplan-Meier curves. The overall survival rate was not significantly different between the two groups.<br /><br />In conclusion, this study showed that patients who received sublobar resection (segmentectomy) had a lower rate of upstaging than those who underwent lobectomy. Additionally, patients who were upstaged after segmentectomy had similar overall survival compared to those who were upstaged after lobectomy. These findings suggest that segmentectomy may be a viable treatment option for patients with tumors ranging from 2cm to 3cm.

Keywords

upstaging

overall survival

tumors

surgical treatments

lung cancer

segmentectomy

lobectomy

stage I non-small-cell lung cancer

pathological stage

viable treatment option